Wall Street analyst estimates for OraSure Technologies, Inc. (OSUR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.23 | ||
| 2026-08-05 | $0.09 | $-0.27 | +133.3% |
| 2026-05-06 | $-0.32 | $-0.23 | -39.1% |
| 2026-02-25 | $-0.27 | $-0.17 | -58.8% |
| 2025-11-05 | $-0.19 | $-0.16 | -18.8% |
| 2025-08-05 | $-0.26 | $-0.19 | -36.8% |
| 2025-05-07 | $-0.18 | $-0.15 | -20.0% |
| 2025-02-25 | $-0.14 | $-0.05 | -180.0% |
Valuation Ratios
| Price / Book | 0.73 |
| EV / EBITDA | -2.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $122.8M | $167.1M | $181.7M | $154.6M | $171.7M | $233.7M | $387.5M | $405.5M | $185.8M | $115.0M |
| Cost of Revenue | $40.2M | $68.1M | $68.1M | $60.0M | $69.9M | $116.1M | $239.0M | $226.1M | $109.6M | $66.8M |
| Gross Profit | $82.6M | $99.0M | $113.6M | $94.6M | $101.9M | $117.6M | $148.4M | $179.4M | $76.2M | $48.2M |
| Research & Development | $9.8M | $13.4M | $16.2M | $19.6M | $31.0M | $34.2M | $36.2M | $33.2M | $24.4M | $42.5M |
| Selling, General & Admin | $58.0M | $57.9M | $58.1M | $66.0M | $76.7M | $95.1M | $117.4M | $92.2M | $72.4M | $73.8M |
| Operating Expenses | $67.8M | $71.2M | $74.3M | $85.6M | $107.8M | $129.2M | $153.7M | $125.3M | $96.8M | $116.3M |
| Operating Income | $14.9M | $27.7M | $39.3M | $9.0M | -$5.9M | -$11.6M | -$5.2M | $54.1M | -$20.6M | -$68.1M |
| EBITDA | $20.6M | $34.1M | $45.7M | $16.3M | $3.5M | $2.4M | -$1.7M | $76.2M | -$6.8M | -$57.0M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | $20.3M | $41.0M | $31.7M | $21.3M | -$3.5M | -$9.3M | -$15.7M | $56.3M | -$17.7M | -$66.9M |
| Income Tax | $603000 | $10.1M | $11.3M | $4.7M | $11.4M | $13.7M | $1.5M | $2.6M | $1.8M | $1.8M |
| Net Income | $19.7M | $30.9M | $20.4M | $16.7M | -$14.9M | -$23.0M | -$17.1M | $53.7M | -$19.5M | -$68.7M |
| EPS | $0.35 | $0.52 | $0.33 | $0.27 | $-0.22 | $-0.32 | $-0.25 | $0.73 | $-0.26 | $-0.94 |
| EPS (Diluted) | $0.35 | $0.51 | $0.33 | $0.27 | $-0.22 | $-0.32 | $-0.25 | $0.72 | $-0.26 | $-0.94 |
| Shares Outstanding (Diluted) | $56.5M | $61.0M | $62.5M | $62.2M | $67.5M | $72.0M | $72.5M | $74.4M | $74.4M | $73.5M |
Price
| Price | $3.49 |
| Market Cap | $240M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CATX · GNFT · NAUT · NTHI · NYXH · PRE · PROF
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of OSUR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks